Amoneta at CTAD 2024: Introducing our Research on Advancing Alzheimer’s Disease Stratification
We are excited to announce that our team will not only be attending but also presenting at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference. During the second poster session on October 31st, we will present our poster number 00492, which introduces an innovative approach to Alzheimer’s patient stratification by combining “static” genetic data from our APO-Easy® and NeuroDeGene® genotyping tools, with dynamic biomarker signatures through AI algorithms. Our resea...
